BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33207202)

  • 1. H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation.
    Harutyunyan AS; Chen H; Lu T; Horth C; Nikbakht H; Krug B; Russo C; Bareke E; Marchione DM; Coradin M; Garcia BA; Jabado N; Majewski J
    Cell Rep; 2020 Nov; 33(7):108390. PubMed ID: 33207202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis.
    Harutyunyan AS; Krug B; Chen H; Papillon-Cavanagh S; Zeinieh M; De Jay N; Deshmukh S; Chen CCL; Belle J; Mikael LG; Marchione DM; Li R; Nikbakht H; Hu B; Cagnone G; Cheung WA; Mohammadnia A; Bechet D; Faury D; McConechy MK; Pathania M; Jain SU; Ellezam B; Weil AG; Montpetit A; Salomoni P; Pastinen T; Lu C; Lewis PW; Garcia BA; Kleinman CL; Jabado N; Majewski J
    Nat Commun; 2019 Mar; 10(1):1262. PubMed ID: 30890717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
    Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
    Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
    Chan KM; Fang D; Gan H; Hashizume R; Yu C; Schroeder M; Gupta N; Mueller S; James CD; Jenkins R; Sarkaria J; Zhang Z
    Genes Dev; 2013 May; 27(9):985-90. PubMed ID: 23603901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma.
    Stafford JM; Lee CH; Voigt P; Descostes N; Saldaña-Meyer R; Yu JR; Leroy G; Oksuz O; Chapman JR; Suarez F; Modrek AS; Bayin NS; Placantonakis DG; Karajannis MA; Snuderl M; Ueberheide B; Reinberg D
    Sci Adv; 2018 Oct; 4(10):eaau5935. PubMed ID: 30402543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
    Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
    Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.
    Piunti A; Smith ER; Morgan MAJ; Ugarenko M; Khaltyan N; Helmin KA; Ryan CA; Murray DC; Rickels RA; Yilmaz BD; Rendleman EJ; Savas JN; Singer BD; Bulun SE; Shilatifard A
    Sci Adv; 2019 Jul; 5(7):eaax2887. PubMed ID: 31281901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
    Sarthy JF; Meers MP; Janssens DH; Henikoff JG; Feldman H; Paddison PJ; Lockwood CM; Vitanza NA; Olson JM; Ahmad K; Henikoff S
    Elife; 2020 Sep; 9():. PubMed ID: 32902381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression.
    Jain SU; Khazaei S; Marchione DM; Lundgren SM; Wang X; Weinberg DN; Deshmukh S; Juretic N; Lu C; Allis CD; Garcia BA; Jabado N; Lewis PW
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27354-27364. PubMed ID: 33067396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
    Pajovic S; Siddaway R; Bridge T; Sheth J; Rakopoulos P; Kim B; Ryall S; Agnihotri S; Phillips L; Yu M; Li C; Milos S; Patel P; Srikanthan D; Huang A; Hawkins C
    Nat Commun; 2020 Dec; 11(1):6216. PubMed ID: 33277484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
    Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
    Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
    Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
    Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.
    Krug B; De Jay N; Harutyunyan AS; Deshmukh S; Marchione DM; Guilhamon P; Bertrand KC; Mikael LG; McConechy MK; Chen CCL; Khazaei S; Koncar RF; Agnihotri S; Faury D; Ellezam B; Weil AG; Ursini-Siegel J; De Carvalho DD; Dirks PB; Lewis PW; Salomoni P; Lupien M; Arrowsmith C; Lasko PF; Garcia BA; Kleinman CL; Jabado N; Mack SC
    Cancer Cell; 2019 May; 35(5):782-797.e8. PubMed ID: 31085178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone H3K27M Mutation in Brain Tumors.
    El-Hashash AHK
    Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
    McCabe MT; Graves AP; Ganji G; Diaz E; Halsey WS; Jiang Y; Smitheman KN; Ott HM; Pappalardi MB; Allen KE; Chen SB; Della Pietra A; Dul E; Hughes AM; Gilbert SA; Thrall SH; Tummino PJ; Kruger RG; Brandt M; Schwartz B; Creasy CL
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2989-94. PubMed ID: 22323599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
    Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
    Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling.
    Herz HM; Morgan M; Gao X; Jackson J; Rickels R; Swanson SK; Florens L; Washburn MP; Eissenberg JC; Shilatifard A
    Science; 2014 Aug; 345(6200):1065-70. PubMed ID: 25170156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of H3.3G34V mutation on genomic H3K36 and H3K27 methylation patterns in isogenic pediatric glioma cells.
    Huang TY; Piunti A; Qi J; Morgan M; Bartom E; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2020 Dec; 8(1):219. PubMed ID: 33287886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.
    Fang D; Gan H; Cheng L; Lee JH; Zhou H; Sarkaria JN; Daniels DJ; Zhang Z
    Elife; 2018 Jun; 7():. PubMed ID: 29932419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.